Public Profile

Adimab

Adimab, a leading biotechnology company headquartered in the United States, was founded in 2007 and has since established itself as a pioneer in the field of antibody discovery and development. With a strong operational presence in key regions across the US and Europe, Adimab focuses on providing innovative solutions for therapeutic antibody generation, utilising its proprietary platform to streamline the discovery process. The company’s core offerings include a robust suite of services that enable partners to develop high-quality monoclonal antibodies efficiently. Adimab's unique approach combines advanced technology with a deep understanding of immunology, positioning it as a trusted partner for pharmaceutical and biotechnology firms. Notable achievements include collaborations with major industry players, solidifying its reputation as a leader in the antibody discovery landscape.

DitchCarbon Score

How does Adimab's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

13

Industry Average

Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

14

Industry Benchmark

Adimab's score of 13 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.

35%

Adimab's reported carbon emissions

Adimab, headquartered in the US, currently does not have publicly available carbon emissions data for recent years, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of detailed information, it is essential to monitor Adimab's future disclosures regarding their climate commitments and sustainability efforts.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Adimab's primary industry is Chemicals nec, which is medium in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Adimab is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Adimab is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero

Was this information valuable to you?

Similar Organizations

IONTAS Limited

GB
Research and development services (73)
Updated 30 days ago

Genovac AG

DE
Updated about 2 months ago
DitchCarbon Score

Alloy Therapeutics, Inc.

US
Health and social work services (85)
Updated 12 days ago

Zymeworks Inc.

US
Health and social work services (85)
Updated 23 days ago

Twist Bioscience Corporation

US
Health and social work services (85)
Updated 4 days ago

AbCellera

CA
Education services (80)
Updated 30 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers